This prospective study evaluated the safety and effectiveness of percutaneous sclerotherapy in the treatment of secondary Budd-Chiari syndrome due to hepatic venous malformations (HVMs). Four patients (mean age, 40 years; 3 women) with 5 HVMs underwent 7 sessions of percutaneous sclerotherapy with a mixture of bleomycin and lipiodol. All patients had chronic Budd-Chiari syndrome, determined based on imaging findings, with the main symptom being abdominal discomfort and distention. On physical examination, 2 patients had ascites and the other 2 had an epigastric mass. The indication for treatment was intractable abdominal symptoms due to hepatic and/or inferior vena cava (IVC) outflow compression. All procedures were technically successful, with no major complications. Three patients underwent a second session because of incomplete IVC decompression. The patients’ symptoms completely resolved at 6 and 12 months of follow-up. There was a significant reduction in lesion volume (P = .007) and an increase in IVC luminal area (P = .018) at 12 months of follow-up.

这项前瞻性研究评估了经皮硬化疗法治疗肝静脉畸形 (HVM) 引起的继发性 Budd-Chiari 综合征的安全性和有效性。4 名患有 5 个 HVM 的患者（平均年龄 40 岁；3 名女性）接受了 7 次使用博来霉素和碘油混合物的经皮硬化疗法。所有患者均患有慢性布加综合征，根据影像学检查结果确定，主要症状为腹部不适和腹胀。体格检查中，2 例患者有腹水，另外 2 例患者有上腹部肿块。治疗的适应症是由于肝和/或下腔静脉 (IVC) 流出受压导致的顽固性腹部症状。所有程序在技术上都是成功的，没有重大并发症。由于 IVC 减压不完全，三名患者接受了第二次治疗。患者的症状在随访 6 个月和 12 个月时完全消失。病灶体积显着减少（P = .007）和 在 12 个月的随访时 IVC 管腔面积增加（P = .018）。